Keep $ONCS on watch.  Had a quick pullback this

Keep $ONCS on watch.  Had a quick pullback this morning.  The company is set to announce pre-lim data for its Phase 2 clinical trials.  First announcment is this Friday and then a second annoucement in mid-November.  If the results of the trials are decent, I would expect the $0.445 it is trading at to be a great entry point.  However, keep in mind the stock is trading up 100% since the announcement was made last week regarding the data announcements.  The pullback this morning was helpful for chartists, although positive news can have a short-term impact on the pps that will trump the technical analysis (i.e. this would be a trade as the price will reset).  Just an FYI for now, I will keep you all posted if I hear anymore details regarding this weeks data annoucement.

http://www.otcmarkets.com/stock/ONCS/company-info

Analysis from a recent Seeking Alpha article:

http://seekingalpha.com/article/931391-5-big-...-wednesday

OncoSec Medical ( ONCS.OB ) has rallied 80% in the last month alone with a gain of 25% on Wednesday. The company had announced that it would be presenting preliminary data for its Phase 2 Merkel cell carcinoma trial on October 26 and that it would be presenting Phase 2 data on its metastatic melanoma trial on November 15. This is what led to most of its gains during the last month. However, on Wednesday the company announced that it received authorization to CE mark its proprietary gene and drug delivery platform, OncoSec Medical System (OMS). This medical system is used for both the company's ImmunoPulse and NeoPulse systems, which is a form of immunotherapy and chemotherapy, respectively. The company's device uses electrical currents to create pores in the cells of cancer tumors as a form of targeted therapy. The company has been under-the-radar, but now appears to be trending higher, with data presentations expected to begin next week. I think it could be a promising stock to watch, as the market is obviously expecting good results-and judging by its earlier trials, the data could very well lead to larger gains. With the company's shares now trading at elevated levels, investors are advised to perform considerable due diligence to ascertain their own risk/reward for this budding biotech.